Skip to main content
Clinical Trials/NCT05278897
NCT05278897
Unknown
Not Applicable

Soft Tissue Adapted Hyaluronic Acid Functional Evaluation (SAFE): A Prospective Study

Global Research Solutions0 sites200 target enrollmentMarch 14, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Elbow Tendinopathy
Sponsor
Global Research Solutions
Enrollment
200
Primary Endpoint
Visual Analog Scale (VAS) Pain
Last Updated
4 years ago

Overview

Brief Summary

Soft Tissue Adapted Biocompatible Hyaluronic Acid, or STABHA™, has demonstrated varying degrees efficacy in patients treated for common musculoskeletal tendinopathies and ligament injuries, such as ankle sprains, lateral elbow tendinopathy, and rotator cuff tendinopathies. Factors associated with prognosis following treatment remain largely unknown. Identifying appropriate patient populations for use of STABHA™ is a necessary first step to facilitate the design of future clinical trials in the management of acute and chronic musculoskeletal soft-tissue injuries.

Registry
clinicaltrials.gov
Start Date
March 14, 2022
End Date
May 13, 2024
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Global Research Solutions
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients 18 years of age or older.
  • Having a STABHA™ injection for the treatment of:
  • Acute first or second degree ankle sprain (e.g. occurred within the past 48 hours).
  • Lateral epicondylitis (tennis elbow).
  • Informed consent obtained.

Exclusion Criteria

  • Medical contraindication to STABHA™.
  • Previous treatment with STABHA™.
  • Ankle or foot fracture.
  • Bilateral ankle sprain.
  • Previous ankle sprain in the past 12 months.
  • Prior surgical management of the ankle or elbow.
  • Current or anticipated incarceration.
  • Terminal illness with expected survival less than 90 days.
  • Currently enrolled in a study that does not permit co-enrollment.
  • Unable to obtain informed consent due to language barriers.

Outcomes

Primary Outcomes

Visual Analog Scale (VAS) Pain

Time Frame: 12 months

A 100mm visual analog scale, with 0 representing no pain and 100 representing the worst pain imaginable. The patient will place an 'X' on the line which represents their current pain.

Secondary Outcomes

  • Adverse Events(12 months)
  • EuroQol-5 Dimensions (EQ-5D)(12 months)
  • 12-Item Short Form Survey Version 1 (SF-12V1)(12 months)
  • Pain medication use(12 months)

Similar Trials